(thirdQuint)MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma.

 The primary objective of this study is to define the tolerability and safety of MLN9708 (ixazomib) administered on a day 1,8,15 every 28 day schedule up to 4mg in combination with fixed doses of panobinostat and dexamethasone in patients with relapsed or refractory myeloma.

 The secondary objectives of this study are to assess response and clinical benefit response rates according to international uniform response criteria and adapted EBMT criteria, respectively.

 And to assess progression-free survival (PFS) and overall survival (OS).

.

 MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma@highlight

This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma.

 This study will also look at the response and clinical benefit of the treatment and the progression-free survival and overall survival of study participants.

